Fifth Third Bancorp Sells 371 Shares of STERIS plc (NYSE:STE)

Fifth Third Bancorp reduced its stake in shares of STERIS plc (NYSE:STEFree Report) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,477 shares of the medical equipment provider’s stock after selling 371 shares during the period. Fifth Third Bancorp’s holdings in STERIS were worth $509,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. West Coast Financial LLC lifted its holdings in shares of STERIS by 2.8% during the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock worth $398,000 after acquiring an additional 45 shares during the last quarter. SkyView Investment Advisors LLC raised its stake in shares of STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after acquiring an additional 51 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in shares of STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 76 shares during the last quarter. Metis Global Partners LLC raised its stake in shares of STERIS by 1.6% during the third quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $1,322,000 after acquiring an additional 84 shares during the last quarter. Finally, Cranbrook Wealth Management LLC raised its stake in shares of STERIS by 4.3% during the fourth quarter. Cranbrook Wealth Management LLC now owns 2,159 shares of the medical equipment provider’s stock valued at $444,000 after acquiring an additional 90 shares during the last quarter. 94.69% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on STE shares. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Monday, November 18th. StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Finally, Stephens reiterated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $262.50.

Check Out Our Latest Research Report on STE

Insider Transactions at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.14% of the company’s stock.

STERIS Price Performance

Shares of NYSE STE opened at $221.66 on Friday. The stock has a market capitalization of $21.88 billion, a P/E ratio of 50.61 and a beta of 0.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24. The company’s 50-day moving average is $211.90 and its 200 day moving average is $224.77.

STERIS (NYSE:STEGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.03 earnings per share. On average, sell-side analysts expect that STERIS plc will post 9.11 earnings per share for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 annualized dividend and a dividend yield of 1.03%. STERIS’s dividend payout ratio is presently 52.05%.

About STERIS

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.